PEA is an autacoid, an endogenous produced healing molecule. Autacoid Medicine will become a major breakthrough in the 21st century!
In a paper ‘Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Pro-inflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.’ various researchers from Italy proved that palmitoylethanolamide can counteract inflammatory side effects
The authors point point out that multiple sclerosis (MS), a chronic autoimmune and inflammatory disease of the central nervous system, can be treated by subcutaneous administration of interferon (IFN)-β1a, but this often leads to adverse events (AEs) such as pain, myalgia, and erythema at the injection site.
A randomized, double-blind, placebo-controlled study was conducted to test the effect of ultrafine PEA added to IFN-β1a for the treatment of clinically defined RR-MS, during one year.
Patients with MS receiving EA perceived experienced less pain sensation at the injection site. A significant improvement in QoL was observed under PEA treatment, and PEA was well tolerated.
On one hand the authors found a clear increase of palmitoylethanolamide plasma levels, as well as a significant reduction of interferon-γ, tumor necrosis factor-α, and interleukin-17 compared with the placebo group.
These results suggest that PEA could become an add-on therapy for the treatment of IFN-β1a-related adverse effects in RR-MS.
Source: Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, Calignano A, Muccioli GG, Orefice G. Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics. 2016 Feb 8.